Our development portfolio includes novel oncology and supportive care product candidates.

Discovery Pre-Clinical Phase 1 Phase 2 Phase 3 Registration

Compound

Indication

Phase


Niraparib + anti-PD-1 mAb & niraparib monotherapy

Advanced NSCLC, Squamous Cell Carcinoma of the Lung

Phase 2

Niraparib + bevacizumab

Ovarian Cancer (AVANOVA)*

Phase 2

Niraparib + chemotherapy

Ewing's Sarcoma**

Phase 1

TSR-042 (anti-PD-1 mAb)

Various tumor types

Phase 1

TSR-042 +/- bevacizumab + niraparib or carboplatin-paclitaxel

Advanced or Metastatic Cancer

Phase 1

TSR-022 (anti-TIM-3 mAb)

Various tumor types (AMBER)

Phase 1

Anti-LAG-3/PD-1 antibody

Various tumor types

Discovery

Undisclosed small molecule I-O candidates

Various tumor types

Discovery


* In collaboration with ENGOT, the European Network for Gynaecological Oncological Trial groups
** In collaboration with SARC, the Sarcoma Alliance for Research through Collaboration

Upon successful development and regulatory approval of any of our product candidates we intend to make them available to cancer patients in North America, Europe and China through our own commercialization efforts and to establish a network of licensees and distributors in other geographic areas.